- Health Topics
- The Science
- Grants and Training
- News and Events
- About NHLBI
All News
|
News Release
The National Institutes of Health awarded nearly $470 million to build a national study population of diverse research volunteers and support large-scale studies on the long-term effects of COVID-19. The NIH Researching COVID to Enhance Recovery (RECOVER) Initiative made the parent award to New York University (NYU) Langone Health, New York City,...
Showing 10 out of 84 results
|
News Release
The National Institutes of Health awarded nearly $470 million to build a national study population of diverse research volunteers and support large-scale studies on the long-term effects of COVID-19. The NIH Researching COVID to Enhance Recovery (RECOVER) Initiative made the parent award to New York University (NYU) Langone Health, New York City,...
|
Research Feature
When COVID-19 restrictions closed research laboratories across the country, it meant Erik Kimble, M.D.’s hematology and oncology training came to a virtual crawl. Not surprisingly, Kimble, who completed medical school in Mexico at the height of the swine flu pandemic, was overwhelmed yet again with uncertainty. He spent months preparing for his...
Credit: NIH Image Gallery
|
NHLBI in the Press
A phase 2 study with 59 patients found fostamatinib, a targeted immune therapy used for a rare bleeding disorder, did not result in more adverse outcomes among adults hospitalized for COVID-19 who required assisted breathing support.
|
News Release
The final results of the Clinical Trial of COVID-19 Convalescent Plasma in Outpatients (C3PO) demonstrate that COVID-19 convalescent plasma did not prevent disease progression in a high-risk group of outpatients with COVID-19, when administered within the first week of their symptoms. The trial was stopped in February 2021 due to lack of efficacy...
|
NHLBI in the Press
The final results of the Clinical Trial of COVID-19 Convalescent Plasma in Outpatients (C3PO) demonstrate that COVID-19 convalescent plasma did not prevent disease progression in a high-risk group of outpatients with COVID-19.
|
NHLBI in the Press
As many as one-fifth of patients hospitalized with severe COVID-19 nationwide who may have benefited from treatment with the anti-inflammatory dexamethasone were not given this treatment during the height of the pandemic, according to a study.
|
News Release
A large clinical trial conducted worldwide shows that treating moderately ill hospitalized COVID-19 patients with a full-dose blood thinner reduced their need for organ support, such as mechanical ventilation, and improved their chances of leaving the hospital. However, the use of this treatment strategy for critically ill COVID-19 patients...
|
NHLBI in the Press
After studying antibody levels in 328 patients hospitalized for COVID-19, researchers identified patterns associated with severe inflammation and illness, such as the need for assisted breathing support. This research supports larger efforts to develop targeted treatment.
|
NHLBI in the Press
After studying biomarkers and stool samples in children who had multisystem inflammatory syndrome in children (MIS-C) or COVID-19, researchers identified a pathway involved in gut permeability that may prolong COVID-19 illness and respond to a therapy that’s being tested for celiac disease.